Clinical trial for eye diseases.

Phase 2 clinical trial for assessment of safety and efficacy of a formulation (SKBYOGMA) for eye diseases.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011969

Enrollment

120

Registered

2018-02-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from eye diseases such as dry eyes, eye infection, red eyes, conjunctivitis, swollen eyes etc.

Interventions

Intervention1: SKBYOGMA: Dose: Very small amount Frequency: Minimum one time/day Route: Apply in eyes Duration: 15 days Control Intervention1: No comparator agent: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Patients suffering from eye diseases such as dry eyes, conjunctivitis, red eyes, eye infection, swollen eyes etc.

Exclusion criteria

Exclusion criteria: Human volunteers not suffering from eye diseases such as dry eyes, conjunctivitis, red eyes, eye infection, swollen eyes etc.

Design outcomes

Primary

Measure	Time frame
Freedom from eye diseases such as dry eyes, conjunctivitis, red eyes, eye infection, swollen eyes etc.Timepoint: 1 day	—

Secondary

Measure	Time frame
Freedom from eye diseases such as dry eyes, conjunctivitis, red eyes, eye infection, swollen eyes etc.Timepoint: 15 days	—

Countries

India

Contacts

Public ContactAshok Kumar

SK Biotherapeutics Pvt. Ltd. (Previously SK Biolabs)

ashok846@gmail.com8126688922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026